Navigation Links
Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
Date:7/24/2008

tion.

MyoCell(R) Clinical Therapy is currently being investigated in MARVEL(1), a randomized, double-blind, placebo-controlled, multi-center Phase II/III Trial involving 330 patients. The largest trial of its kind to date, MARVEL is currently enrolling NYHA Class II-IV congestive heart failure patients in approximately 25 of the most important cell therapy centers in the U.S. In the MARVEL Trial, MyoCell(R) is being delivered via a MyoStar(TM) injection catheter(2), in combination with the NOGA(R) XP Cardiac Navigation System. The Principal Investigator for the MARVEL Trial is Warren Sherman, MD, Director, Cardiac Cell-based Endovascular Therapies, Columbia University Medical Center, New York.

"We are very proud of our continued progress with our MyoCell(R) Clinical Therapy and our pre-clinical work with SDF-1," said Howard J. Leonhardt, Bioheart CEO and Chief Technology Officer. "We are currently working with the FDA on obtaining an IND approval for the start of our human trial involving SDF-1."

ABOUT CONGESTIVE HEART FAILURE

Congestive heart failure (CHF), or heart failure, is a condition in which the heart cannot pump enough oxygenated blood to the body's vital organs. People with heart failure find that they cannot exert themselves as they become tired and short of breath. Current therapeutic options include palliative medical therapy (symptom-treating medicine), cardiac assist devices or cardiac transplantation. Heart failure is a leading cause of hospitalizations in people over age 65.

ABOUT MYOCELL(R) CLINICAL CELL THERAPY

MyoCell(R) clinical cell therapy, developed by Bioheart, Inc., is currently being studied as an investigational product in Europe and the U.S. MyoCell(R) clinical cell therapy is intended to be used to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack. The procedure involves a physician removing a small amount of muscle obtained from
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
4. GeoVax Reports Progress on Its AIDS Vaccine Technology
5. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
6. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
7. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
8. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
9. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
10. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... 4 A new, $2.8 million, four-year federal grant ... of Medicine and their collaborators at Wake Forest University ... blood degrades over time and how to address the ... been associated with increased risk for cardiovascular events and ...
(Date:12/4/2009)... Deliveries are Transported ,, PHILADELPHIA, Dec. 4 ... the American Red Cross are hard at work educating ... endure that could potentially put Philadelphia,s blood supply at ... and set up a picket line yesterday when their ...
(Date:12/4/2009)... Imaging, LLC, an independent provider of CT, MRI ... and healthcare providers, is excited to announce it ... Health Care, a nationally-recognized, prestigious gold seal of ... Shared Imaging accreditation is system-wide for its mobile ...
Breaking Medicine Technology:NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 2NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 3Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2The Prem Rawat Foundation Makes Two Grants to Provide Relief in Pakistan 57584 1The Prem Rawat Foundation Makes Two Grants to Provide Relief in Pakistan 57584 2Ohio Healthcare Organization Responds to Healthcare Reform 57581 1Ohio Healthcare Organization Responds to Healthcare Reform 57581 2Ohio Healthcare Organization Responds to Healthcare Reform 57581 3Ohio Healthcare Organization Responds to Healthcare Reform 57581 4Ohio Healthcare Organization Responds to Healthcare Reform 57581 5FDA Warns Consumers Not to Use Stolen Albuterol Sulfate Inhalation Solution and Ipratropium Bromide Inhalation Solution 57579 1FDA Warns Consumers Not to Use Stolen Albuterol Sulfate Inhalation Solution and Ipratropium Bromide Inhalation Solution 57579 2
... TriLipix in Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar ... ... Population, SAN FRANCISCO, June ... dyslipidemia and type 2 diabetes,that were enrolled in a Phase III ...
... Annual Scientific Sessions, SAN FRANCISCO, June 7 ... dose-finding study for its new,injectable diabetes compound AVE0010, ... Association,s (ADA) 68th Annual Scientific Sessions,meeting in San ... was well tolerated and significantly,improved glycemic control versus ...
Other Medicine Technology:Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 2Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 3Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
(Date:12/6/2009)... ORLEANS, Dec. 6 Sickle cell disease, ... blood cells, is one of the most common ... the world, including more than 70,000 Americans.(1) Research ... the American Society of Hematology highlights intriguing studies ... presents for children with this blood disorder, evaluations ...
(Date:12/6/2009)... Treatment site www.sleeping-with-a-sleeping-disorder.com is asking people ... natural sleep aids from around the world to ... cause. The submissions will be compiled in an ... YOU, to be sold from the website in ... of the proceeds ,from sales of the E-book ...
(Date:12/5/2009)... NEW ORLEANSA new three-drug combination has shown in a ... "highly effective regimen" in the treatment of patients newly ... cells in bone marrow, say researchers from Dana-Farber Cancer ... all of the 66 patients treated with the drug ... a "very good partial response rate" in the phase ...
(Date:12/5/2009)... The first Football,for Hope Centre in Khayelitsha in ... (5 December 2009). FIFA President Joseph S. Blatter ... FIFA World Cup Organising Committee,South Africa (OC) CEO ... and Executive Mayor of the City of Cape ...
(Date:12/5/2009)... , , SATURDAY, Dec. 5 (HealthDay News) -- They,re not ... bad reactions to certain holiday traditions and need to ... to the American College of Allergy, Asthma and Immunology ... may choose to decorate with artificial plants, but both ...
Breaking Medicine News(10 mins):Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Keep Asthma, Allergies at Bay for the Holidays 2
... most common reason for hospitalizations, analysis finds , , WEDNESDAY, ... 1.2 million Americans -- roughly equivalent to the population ... government analysis of hospital admissions and costs found. , ... common reason for admission to hospital, and treating these ...
... Pa., July 2 David Belkin died,last February during a ... he is alive to tell about it., On Sunday, ... his hero.,He,ll present Matlaga with the Sudden Cardiac Arrest (SCA) ... Henry Skier, at,13 Hillcrest Rd. (behind Wayne Memorial Hospital) in ...
... and Georgia Reach Statewide Olmstead,Settlement Agreement, WASHINGTON, ... currently institutionalized in Georgia,s,eight public psychiatric hospitals and ... in their communities with appropriate supports,tailored to meet ... settlement,agreement between the state of Georgia and the ...
... to the gym, take simple steps to avoid the ... -- Before heading to the gym, you should brush ... deadly superbug, say doctors from Loyola University. , While ... hospitals and health-care settings, they are on the rise ...
... Medicare Advantage face significant funding cuts under legislation ... by America,s Health,Insurance Plans., As Congress considers ... in Medicare, many are looking at the Medicare ... being considered (H.R. 6331) would,cut $143 million from ...
... 2 New Hampshire seniors,enrolled in Medicare Advantage ... Congress, according to new data released by,America,s Health ... halt the impending cut to physician,payments in Medicare, ... to,pay for the fix. Legislation currently being considered ...
Other Medicine News:Health News:Back From the Dead: Cardiac Arrest Victim Salutes His Rescuer 2Health News:Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 2Health News:Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 3Health News:MRSA Infections Can Bug Fitness Buffs 2Health News:Proposed Congressional Legislation Would Cut $143 Million from the Medicare Advantage Program in Georgia 2Health News:Proposed Congressional Legislation Would Cut $6.6 Million from the Medicare Advantage Program in New Hampshire 2
... EpochXP Workstations provide comprehensive neurological monitoring ... care unit to accurately access your ... over 15 years experience, and a ... EpochXP neurological monitoring systems have a ...
... powerful, multi-modality system capable of performing EP (including ... and train of four testing tests simultaneously. The ... The base weighs only 4.25 lbs. A complete ... desktop PC-based system with a custom cart can ...
... neuromonitoring system especially designed for surgical monitoring ... 16 channels and is equipped with two ... channel can be independently configured as either ... channel. Endeavor amplifiers are based on the ...
... Katena Products, Inc. is the ... dedicated exclusively to ophthalmic surgical ... to over 7,000 customers in ... a global network of distributors, ...
Medicine Products: